Possible reasons include the small effect of each individual SNP,27 as a set of 95 SNPs explained <15% of total lipid variance,28 or the progressive blunting of the genetic effect by advanced ageing as found for BP.29 Thus, our results suggest that genetic profiling of subjects prior to initiation of statin therapy might be clinically irrelevant, and such profiling is not stated in the current ESC/EAS guidelines for the management of dyslipidaemias.3 Nevertheless, several associations were found with the SLCO1B1 gene. This evidence concerns the gene SLCO1B1 and inherited lipid metabolism disorder.